Faculty Collaboration Database

1. Baum LL, Johnson B, Berman S, Graham D, Mold C. C-reactive protein is involved in natural killer cell-mediated lysis but does not mediate effector-target cell recognition. Immunology. 1987 May;61(1):93-9. PMCID: PMC1453307

2. Johnson BD, Kim YB. Characterization of a monoclonal antibody enhancing porcine natural killer cell activity (PNK-E). Cell Immunol. 1990 Jan;125(1):107-19.

3. Johnson BD, Wierda WG, Kim YB. Further characterization of PNK-E: a monoclonal antibody enhancing porcine natural killer cell activity. Cell Immunol. 1991 May;134(2):378-89.

4. Johnson BD, Truitt RL. A decrease in graft-vs.-host disease without loss of graft-vs.-leukemia reactivity after MHC-matched bone marrow transplantation by selective depletion of donor NK cells in vivo. Transplantation. 1992 Jul;54(1):104-12.

5. Wierda WG, Johnson BD, Dato ME, Kim YB. Two distinct porcine natural killer lytic trigger molecules as PNK-E/G7 molecular complex. Cell Immunol. 1993 Feb;146(2):270-83.

6. Johnson BD, Drobyski WR, Truitt RL. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. Bone Marrow Transplant. 1993 Apr;11(4):329-36.

7. Wierda WG, Johnson BD, Dato ME, Kim YB. Induction of porcine granulocyte-mediated tumor cytotoxicity by two distinct monoclonal antibodies against lytic trigger molecules (PNK-E/G7). J Immunol. 1993 Dec 15;151(12):7117-27.

8. Johnson BD, Truitt RL. Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease. Blood. 1995 Jun 01;85(11):3302-12.

9. Truitt RL, Johnson BD. Principles of graft-vs.-leukemia reactivity. Biol Blood Marrow Transplant. 1995 Dec;1(2):61-8.

10. Johnson BD, McCabe C, Hanke CA, Truitt RL. Use of anti-CD3 epsilon F(ab')2 fragments in vivo to modulate graft-versus-host disease without loss of graft-versus-leukemia reactivity after MHC-matched bone marrow transplantation. J Immunol. 1995 May 15;154(10):5542-54.

11. Johnson BD, Hanke CA, Truitt RL. The graft-versus-leukemia effect of post-transplant donor leukocyte infusion. Leuk Lymphoma. 1996 Sep;23(1-2):1-9.

12. Johnson BD, Hanke CA, Becker EE, Truitt RL. Sca1(+)/Mac1(+) nitric oxide-producing cells in the spleens of recipients early following bone marrow transplant suppress T cell responses in vitro. Cell Immunol. 1998 Nov 01;189(2):149-59.

13. Johnson BD, Becker EE, Truitt RL. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets. Biol Blood Marrow Transplant. 1999;5(3):123-32.

14. Truitt RL, Johnson BD, Hanke C, Talib S, Hearst JE. Photochemical treatment with S-59 psoralen and ultraviolet A light to control the fate of naive or primed T lymphocytes in vivo after allogeneic bone marrow transplantation. J Immunol. 1999 Nov 01;163(9):5145-56.

15. Johnson BD, Becker EE, LaBelle JL, Truitt RL. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy. J Immunol. 1999 Dec 15;163(12):6479-87.

16. Johnson BD, Kurup VP, Sussman GL, Arif SA, Kelly KJ, Beezhold DH, Fink JN. Purified and recombinant latex proteins stimulate peripheral blood lymphocytes of latex allergic patients. Int Arch Allergy Immunol. 1999 Dec;120(4):270-9.

17. Banerjee B, Kurup VP, Greenberger PA, Johnson BD, Fink JN. Cloning and expression of Aspergillus fumigatus allergen Asp f 16 mediating both humoral and cell-mediated immunity in allergic bronchopulmonary aspergillosis (ABPA). Clin Exp Allergy. 2001 May;31(5):761-70.

18. Rathore VB, Johnson B, Fink JN, Kelly KJ, Greenberger PA, Kurup VP. T cell proliferation and cytokine secretion to T cell epitopes of Asp f 2 in ABPA patients. Clin Immunol. 2001 Aug;100(2):228-35.

19. Orentas RJ, Schauer D, Bin Q, Johnson BD. Electrofusion of a weakly immunogenic neuroblastoma with dendritic cells produces a tumor vaccine. Cell Immunol. 2001 Oct 10;213(1):4-13.

20. Johnson BD, Dagher N, Stankowski WC, Hanke CA, Truitt RL. Donor natural killer (NK1.1+) cells do not play a role in the suppression of GVHD or in the mediation of GVL reactions after DLI. Biol Blood Marrow Transplant. 2001;7(11):589-95.

21. Bin Q, Johnson BD, Schauer DW, Casper JT, Orentas RJ. Production of macrophage migration inhibitory factor by human and murine neuroblastoma. Tumour Biol. 2002;23(3):123-9.

22. Johnson BD, Taylor PA, Stankowski MC, Talib S, Hearst JE, Blazar BR. Photochemical treatment of donor lymphocytes inhibited their ability to facilitate donor engraftment or increase donor chimerism after nonmyeloablative conditioning or establishment of mixed chimerism. Biol Blood Marrow Transplant. 2002;8(11):581-7.

23. Johnson BD, Konkol MC, Truitt RL. CD25+ immunoregulatory T-cells of donor origin suppress alloreactivity after BMT. Biol Blood Marrow Transplant. 2002;8(10):525-35.

24. Johnson BD, Yan X, Schauer DW, Orentas RJ. Dual expression of CD80 and CD86 produces a tumor vaccine superior to single expression of either molecule. Cell Immunol. 2003 Mar;222(1):15-26.

25. Wilcox DA, Shi Q, Nurden P, Haberichter SL, Rosenberg JB, Johnson BD, Nurden AT, White GC 2nd, Montgomery RR. Induction of megakaryocytes to synthesize and store a releasable pool of human factor VIII. J Thromb Haemost. 2003 Dec;1(12):2477-89.

26. Browning MB, Woodliff JE, Konkol MC, Pati NT, Ghosh S, Truitt RL, Johnson BD. The T cell activation marker CD150 can be used to identify alloantigen-activated CD4(+)25+ regulatory T cells. Cell Immunol. 2004 Feb;227(2):129-39.

27. Rosenblum MD, Olasz E, Woodliff JE, Johnson BD, Konkol MC, Gerber KA, Orentas RJ, Sandford G, Truitt RL. CD200 is a novel p53-target gene involved in apoptosis-associated immune tolerance. Blood. 2004 Apr 01;103(7):2691-8.

28. Yan X, Johnson BD, Orentas RJ. Murine CD8 lymphocyte expansion in vitro by artificial antigen-presenting cells expressing CD137L (4-1BBL) is superior to CD28, and CD137L expressed on neuroblastoma expands CD8 tumour-reactive effector cells in vivo. Immunology. 2004 May;112(1):105-16. PMCID: PMC1782467

29. Xia G, Kovochich M, Truitt RL, Johnson BD. Tracking ex vivo-expanded CD4+CD25+ and CD8+CD25+ regulatory T cells after infusion to prevent donor lymphocyte infusion-induced lethal acute graft-versus-host disease. Biol Blood Marrow Transplant. 2004 Nov;10(11):748-60.

30. Gershan JA, Johnson BD, Weber J, Schauer DW, Natalia N, Behnke S, Burns K, Maloney KW, Warwick AB, Orentas RJ. Immediate transfection of patient-derived leukemia: a novel source for generating cell-based vaccines. Genet Vaccines Ther. 2005 Jun 21;3(1):4. PMCID: PMC1182385

31. Johnson BD, Gershan JA, Natalia N, Zujewski H, Weber JJ, Yan X, Orentas RJ. Neuroblastoma cells transiently transfected to simultaneously express the co-stimulatory molecules CD54, CD80, CD86, and CD137L generate antitumor immunity in mice. J Immunother. 2005;28(5):449-60.

32. Fang J, Hodivala-Dilke K, Johnson BD, Du LM, Hynes RO, White GC 2nd, Wilcox DA. Therapeutic expression of the platelet-specific integrin, alphaIIbbeta3, in a murine model for Glanzmann thrombasthenia. Blood. 2005 Oct 15;106(8):2671-9. PMCID: PMC1895311

33. Barrios CS, Johnson BD, D Henderson J Jr, Fink JN, Kelly KJ, Kurup VP. The costimulatory molecules CD80, CD86 and OX40L are up-regulated in Aspergillus fumigatus sensitized mice. Clin Exp Immunol. 2005 Nov;142(2):242-50. PMCID: PMC1809515

34. Yan X, Orentas RJ, Johnson BD. Tumor-derived macrophage migration inhibitory factor (MIF) inhibits T lymphocyte activation. Cytokine. 2006 Feb 21;33(4):188-98. PMCID: PMC2018658

35. Xia G, Truitt RL, Johnson BD. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras. Biol Blood Marrow Transplant. 2006 Apr;12(4):397-407.

36. Shi Q, Wilcox DA, Fahs SA, Fang J, Johnson BD, DU LM, Desai D, Montgomery RR. Lentivirus-mediated platelet-derived factor VIII gene therapy in murine haemophilia A. J Thromb Haemost. 2007 Feb;5(2):352-61.

37. Zhou Q, Johnson BD, Orentas RJ. Cellular immune response to an engineered cell-based tumor vaccine at the vaccination site. Cell Immunol. 2007 Feb;245(2):91-102. PMCID: PMC1949498

38. Johnson BD, Jing W, Orentas RJ. CD25+ regulatory T cell inhibition enhances vaccine-induced immunity to neuroblastoma. J Immunother. 2007;30(2):203-14.

39. Jing W, Orentas RJ, Johnson BD. Induction of immunity to neuroblastoma early after syngeneic hematopoietic stem cell transplantation using a novel mouse tumor vaccine. Biol Blood Marrow Transplant. 2007 Mar;13(3):277-92. PMCID: PMC1852542

40. Chen X, Vodanovic-Jankovic S, Johnson B, Keller M, Komorowski R, Drobyski WR. Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. Blood. 2007 Nov 15;110(10):3804-13. PMCID: PMC2077325

41. Kurup VP, Barrios CS, Raju R, Johnson BD, Levy MB, Fink JN. Immune response modulation by curcumin in a latex allergy model. Clin Mol Allergy. 2007 Jan 25;5:1. PMCID: PMC1796894

42. Keever-Taylor CA, Browning MB, Johnson BD, Truitt RL, Bredeson CN, Behn B, Tsao A. Rapamycin enriches for CD4(+) CD25(+) CD27(+) Foxp3(+) regulatory T cells in ex vivo-expanded CD25-enriched products from healthy donors and patients with multiple sclerosis. Cytotherapy. 2007;9(2):144-57.

43. Zheng J, Kohler ME, Chen Q, Weber J, Khan J, Johnson BD, Orentas RJ. Serum from mice immunized in the context of Treg inhibition identifies DEK as a neuroblastoma tumor antigen. BMC Immunol. 2007 Mar 30;8:4. PMCID: PMC1852119

44. Zhou Q, Yan X, Gershan J, Orentas RJ, Johnson BD. Expression of macrophage migration inhibitory factor by neuroblastoma leads to the inhibition of antitumor T cell reactivity in vivo. J Immunol. 2008 Aug 01;181(3):1877-86. PMCID: PMC3804024

45. Yan X, Johnson BD, Orentas RJ. Induction of a VLA-2 (CD49b)-expressing effector T cell population by a cell-based neuroblastoma vaccine expressing CD137L. J Immunol. 2008 Oct 01;181(7):4621-31. PMCID: PMC2975591

46. Jing W, Gershan JA, Johnson BD. Depletion of CD4 T cells enhances immunotherapy for neuroblastoma after syngeneic HSCT but compromises development of antitumor immune memory. Blood. 2009 Apr 30;113(18):4449-57. PMCID: PMC2676098

47. Johnson B, Drobyski W, Blazar B, Korngold R. Robert Truitt tribute. Biol Blood Marrow Transplant. 2010 Jan;16(1):143-4.

48. Cludts S, Decaestecker C, Johnson B, Lechien J, Leroy X, Kindt N, Kaltner H, André S, Gabius HJ, Saussez S. Increased expression of macrophage migration inhibitory factor during progression to hypopharyngeal squamous cell carcinoma. Anticancer Res. 2010 Sep;30(9):3313-9.

49. Kohler ME, Johnson BD, Palen K, Chen QR, Khan J, Orentas RJ. Tumor antigen analysis in neuroblastoma by serological interrogation of bioinformatic data. Cancer Sci. 2010 Nov;101(11):2316-24. PMCID: PMC3103783

50. Kohler ME, Hallett WH, Chen QR, Khan J, Johnson BD, Orentas RJ. Early expression of stem cell-associated genes within the CD8 compartment after treatment with a tumor vaccine. Cell Immunol. 2010;265(1):65-73. PMCID: PMC2935508

51. Jing W, Yan X, Hallett WH, Gershan JA, Johnson BD. Depletion of CD25⁺ T cells from hematopoietic stem cell grafts increases posttransplantation vaccine-induced immunity to neuroblastoma. Blood. 2011 Jun 23;117(25):6952-62. PMCID: PMC3128485

52. Hallett WH, Jing W, Drobyski WR, Johnson BD. Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade. Biol Blood Marrow Transplant. 2011 Aug;17(8):1133-45.

53. Palen KA, Jing W, Weber JJ, Tilkens SB, Chan AM, Johnson BD, Gershan JA. Separation and Characterization of Epithelial and Mesenchymal-like Murine Mammary Tumor Cells Reveals Epithelial Cell Differentiation Plasticity and Enhanced Tumorigenicity of Epithelial-enriched Tumor Cells. Cancer Microenviron. 2013 Apr;6(1):79-89. PMCID: PMC3601216

54. Yan X, Doffek K, Yin C, Krein M, Phillips M, Sugg SL, Johnson B, Shilyansky J. Annexin-V promotes anti-tumor immunity and inhibits neuroblastoma growth in vivo. Cancer Immunol Immunother. 2012 Nov;61(11):1917-27. PMCID: PMC11029734

55. Barr KM, Jing W, Hallett WHD, Gershan JA, Johnson BD; Examining T Cells at Vaccine Sites of Tumor-Bearing Hosts Provides Insights to Dysfunctional T Cell Immunity, J Immunother. 2013 Jan;36(1):41-51

56. Zhang G, Chen F, Cao Y, Johnson Bl, and See WA: HMGB1 release by urothelial carcinoma cells is required for the in vivo antitumor response to Bacillus Calmette-Guérin. Journal of Urology, 2013 Apr 189(4):1541-6

57. Kindt N, Preillon J, Kaltner H, Gabius HJ, Chevalier D, Johnson BD., Megalizzi V, Decaestecker C, Laurent G, and Saussez S: J Macrophage migration inhibitory factor in head and neck squamous cell carcinoma: clinical and experimental studies. J of Cancer Res and Clin Oncol., 2013 May;139(5):727-37

58. Kearl TJ, Jing W J, Gershan JA, Johnson BD; Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma:J Immunol 2013 Jun 1;190(11):5620-8

59. Jing W, Gershan JA, Weber J, Tlomak D, McOlash L, Sabatos-Peyton C, Johnson BD. Combined Immune Checkpoint Protein Blockade and Low Dose Whole Body Irradiation as Immunotherapy for Myeloma. J Immunother Cancer. 2015 Jan 20;3(1):2.

60. Gershan JA, Barr KM, Weber JJ, Jing W, Johnson BD.Immune modulating effects of cyclophosphamide and treatment with tumor lysate/CpG synergize to eliminate murine neuroblastoma.J Immunother Cancer. 2015 Jun 16;3:24.PMCID:PMC4469315

1. Truitt RL JB. Graft-versus-host disease and the graft-versus-leukemia effect: Lessons from allogeneic bone marrow transplantation. In: T. Spitzer and A. Mazumder, ed. Immunotherapy and bone marrow transplantation. Armonk, NY: Futura Publishing; 1995.

2. Truitt RL, Johnson BD, McCabe C, Weiler MB. Graft-versus-leukemia. In: JLM Ferrara and S Burnakoff, ed. Graft-vs-host disease: Immunology, pathophysiology and treatment. Second ed. New York: Marcel Dekker; 1997.

3. Yan X, Orentas RJ, Johnson BD. Tumor-derived macrophage migration inhibitory factor (MIF) inhibits T lymphocyte activation. Cytokine. 2006 Feb 21;33(4):188-98. PMCID: PMC2018658

4. Orentas RJ, Kohler ME, Johnson BD. Suppression of anti-cancer immunity by regulatory T cells: back to the future. Semin Cancer Biol. 2006 Apr;16(2):137-49.

5. Truitt RL, Horowitz MM, Atasoylu AA, Drobyski WD, Johnson BD, LeFever AV. Graft-versus-Leukemia Effect of Allogeneic Bone Marrow Transplantation: Clinical and Experimental Aspects of Late Leukemia Relapse. IN: Cellular Immune Mechanisms and Tumor Dormancy (THM Stewart, ed.), CRC Press, Inc., Boca Raton, p 111, 1992.

6. Jing W, Johnson BD. Tumor Vaccination after Autologous HSCT: What has been Learned from Experimental Models? IN: Cancer Vaccines and Tumor Immunity (R. Orentas, B. Johnson and J. Hodge, eds.), John Wiley & Sons, Inc., Hoboken, NJ, pp. 205-215, 2008.

7. Xia G, He J, Leventhal JR. Ex vivo-expanded natural CD4+CD25+ regulatory T cells synergize with host T-cell depletion to promote long-term survival of allografts. Am J Transplant. 2008 Feb;8(2):298-306.

8. Truitt RL, Korngold R, Johnson BD, Townsend R, Blazar RB. Experimental Animal Models in the Study of GVL Reactions. IN: The Graft Versus Leukemia Effect In Allogeneic Stem Cell Transplantation, (J. Barrett and Y. Jiang, eds.), Marcel Dekker, New York, 2000, p. 39.

9. Kearl TJ, Jing W, Gershan JA, Johnson BD. Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma. J Immunol. 2013 Jun 01;190(11):5620-8. PMCID: PMC3891840

10. Kearl TJ, Jing W, Gershan JA, Johnson BD Programmed Death Receptor-1/Programmed Death Receptor Ligand-1 Blockade after Transient Lymphodepletion to Treat Myeloma. J Immunol. 2013 Apr 24

11. Truitt RL, Korngold R, Johnson BD, Townsend R, Blazar RB. Experimental Animal Models in the Study of GVL Reactions. IN: The Graft Versus Leukemia Effect In Allogeneic Stem Cell Transplantation, (J. Barrett and Y. Jiang, eds.), Marcel Dekker, New York, 2000,

12. Xia G, Zhang Z, Johnson BD: Prevention of Heart Allograft Rejection by Immunotherapy with Ex Vivo-Expanded Foxp3+CD4 +CD25+ Natural Regulatory T Cells. IN: Heart Transplantation: Indications and Contraindications, Procedures and Complications (C.T. Fleming ed.), Nova Science Publishers, Inc., Hauppauge, NY, 2009.

13. Gershan J, Chan A, Chrzanowska-Wodnicka M, Johnson B, Miao Q, Ramchandran R.: Endothelial and Accessory Cell Interactions in Neuroblastoma Tumor Microenvironment. IN: Research Directions in Tumor Angiogenesis (J. Chai ed.), Intech Open Access, ISBN 978-953-51-0963-1, 2013.

14. Barr KM, Gershan JA,Johnson BD: Hematopoietic Stem Cell Transplantation and Lymphodepletion for the Treatment of Cancer. IN: Cancer Immunology: Translational Medicine from Bench to Bedside (N. Rezaei ed.), Springer, submitted for publication.

15. Jing W, Gershan JA, Weber J, Tlomak D, McOlash L, Sabatos-Peyton C, Johnson BD. Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma. J Immunother Cancer. 2015;3(1):2. PMCID: PMC4302511

16. Palen KA, Jing W, Weber JJ, Tilkens SB, Chan AM, Johnson BD, Gershan JA. Erratum to: Separation and Characterization of Epithelial and Mesenchymal-like Murine Mammary Tumor Cells Reveals Epithelial Cell Differentiation Plasticity and Enhanced Tumorigenicity of Epithelial-enriched Tumor Cells. Cancer Microenviron. 2016 Apr;9(1):75. PMCID: PMC4842184

17. Cheng G, Zielonka J, Ouari O, Lopez M, McAllister D, Boyle K, Barrios CS, Weber JJ, Johnson BD, Hardy M, Dwinell MB, Kalyanaraman B. Mitochondria-Targeted Analogues of Metformin Exhibit Enhanced Antiproliferative and Radiosensitizing Effects in Pancreatic Cancer Cells. Cancer Res. 2016 Jul 01;76(13):3904-15. PMCID: PMC4930686

18. Palen K, Weber J, Dwinell MB, Johnson BD, Ramchandran R, Gershan JA. E-cadherin re-expression shows in vivo evidence for mesenchymal to epithelial transition in clonal metastatic breast tumor cells. Oncotarget. 2016 Jul 12;7(28):43363-43375. PMCID: PMC5190029

19. Riese MJ, Moon EK, Johnson BD, Albelda SM. Diacylglycerol Kinases (DGKs): Novel Targets for Improving T Cell Activity in Cancer. Front Cell Dev Biol. 2016;4:108. PMCID: PMC5065962

20. Xin G, Schauder DM, Jing W, Jiang A, Joshi NS, Johnson B, Cui W. A Pathogen Boosted Adoptive Cell Transfer Immunotherapy to Treat Solid Tumors, PNAS, Epub ahead of print. PMID: 28069963.

21. Jing W, Gershan JA, Blitzer GC, Palen K, Weber J, McOlash L, Riese M, Johnson BD. Adoptive cell therapy using PD-1⁺ myeloma-reactive T cells eliminates established myeloma in mice. J Immunother Cancer. 2017;5:51. PMCID: PMC5477110

22. Jing W, Gershan JA, Holzhauer S, Weber J, Palen K, McOlash L, Pulakanti K, Wesley E, Rao S, Johnson BD, Riese MJ. T Cells Deficient in Diacylglycerol Kinase ζ Are Resistant to PD-1 Inhibition and Help Create Persistent Host Immunity to Leukemia. Cancer Res. 2017 Oct 15;77(20):5676-5686.

23. Palen K, Thakar M, Johnson BD, Gershan JA. Bone Marrow-derived CD8+ T Cells From Pediatric Leukemia Patients Express PD1 and Expand Ex Vivo Following Induction Chemotherapy. J Pediatr Hematol Oncol. 2019 Nov;41(8):648-652. PMCID: PMC6855330

24. Wesley EM, Xin G, McAllister D, Malarkannan S, Newman DK, Dwinell MB, Cui W, Johnson BD, Riese MJ. Diacylglycerol kinase ζ (DGKζ) and Casitas b-lineage proto-oncogene b-deficient mice have similar functional outcomes in T cells but DGKζ-deficient mice have increased T cell activation and tumor clearance. Immunohorizons. 2018 Apr 01;2(4):107-118. PMCID: PMC6048965

25. Newman DK, Fu G, McOlash L, Schauder D, Newman PJ, Cui W, Rao S, Johnson BD, Gershan JA, Riese MJ. Frontline Science: PECAM-1 (CD31) expression in naïve and memory, but not acutely activated, CD8⁺ T cells. J Leukoc Biol. 2018 Nov;104(5):883-893. PMCID: PMC6195461

26. Tsai S, McOlash L, Jia S, Zhang J, Simpson P, Kaldunski ML, Aldakkak M, Grewal J, Palen K, Dwinell MB, Johnson BD, Mackinnon A, Hessner MJ, Gershan JA. A Serum-Induced Transcriptome and Serum Cytokine Signature Obtained at Diagnosis Correlates with the Development of Early Pancreatic Ductal Adenocarcinoma Metastasis. Cancer Epidemiol Biomarkers Prev. 2019 Apr;28(4):680-689. PMCID: PMC6545232

27. Jing W, McAllister D, Vonderhaar EP, Palen K, Riese MJ, Gershan J, Johnson BD, Dwinell MB. STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models. J Immunother Cancer. 2019 Apr 29;7(1):115. PMCID: PMC6489306

28. Truitt RL, Johnson BD, Korngold R, Townsend R, Blazar BR. Experimental animal models in the study of GVL reactions Allogeneic Immunotherapy for Malignant Diseases. 1 January 2000:39-74.

29. Orentas R, Hodge JW, Johnson BD. Cancer Vaccines and Tumor Immunity Cancer Vaccines and Tumor Immunity. 1 March 2007:1-334.

30. Truitt RL, Horowitz MM, Atasoylu AA, Drobyski WR, Johnson BD, LeFever AV. Graft-versus-leukemia effect of allogeneic bone marrow transplantation: Clinical and experimental aspects of late leukemia relapse Cellular Immune Mechanisms and Tumor Dormancy. 1 January 2017:111-132.

31. Jing W, Chen J, Cai Y, Chen Y, Schroeder JA, Johnson BD, Cui W, Shi Q. Induction of activated T follicular helper cells is critical for anti-FVIII inhibitor development in hemophilia A mice. Blood Adv. 2019 Oct 22;3(20):3099-3110. PMCID: PMC6849959

32. Badar T, Dhakal B, Szabo A, Padmanabhan A, Johnson BD, Heidtke S, Esselmann J, Chhabra S, Hamadani M, Hari P, D'Souza A. An updated single center experience with plerixafor and granulocyte colony-stimulating factor for stem cell mobilization in light chain amyloidosis. J Clin Apher. 2019 Dec;34(6):686-691. PMCID: PMC6957224

33. D'Souza A, Hari P, Pasquini M, Braun T, Johnson B, Lundy S, Couriel D, Hamadani M, Magenau J, Dhakal B, Shah NN, Riwes M, Parkin B, Reddy P, Pawarode A. A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. Biol Blood Marrow Transplant. 2019 Aug;25(8):1492-1497.

34. Shah NN, Maatman T, Hari P, Johnson B. Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies. Front Oncol. 2019;9:146. PMCID: PMC6423158

35. Pan J, Zhang Q, Palen K, Wang L, Qiao L, Johnson B, Sei S, Shoemaker RH, Lubet RA, Wang Y, You M. Potentiation of Kras peptide cancer vaccine by avasimibe, a cholesterol modulator EBioMedicine. 2019.

36. Tsai S, McOlash L, Palen K, Johnson B, Duris C, Yang Q, Dwinell MB, Hunt B, Evans DB, Gershan J, James MA. Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models. BMC Cancer. 2018 Mar 27;18(1):335. PMCID: PMC5870823

37. Drobyski WR, Szabo A, Zhu F, Keever-Taylor C, Hebert KM, Dunn R, Yim S, Johnson B, D'Souza A, Eapen M, Fenske TS, Hari P, Hamadani M, Horowitz MM, Rizzo JD, Saber W, Shah N, Shaw B, Pasquini M. Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-<i>versus</i>-host disease: low incidence of lower gastrointestinal tract disease. Haematologica. 2018 Apr;103(4):717-727. PMCID: PMC5865423

38. Xin G, Schauder DM, Jing W, Jiang A, Joshi NS, Johnson B, Cui W. Pathogen boosted adoptive cell transfer immunotherapy to treat solid tumors. Proc Natl Acad Sci U S A. 2017 Jan 24;114(4):740-745. PMCID: PMC5278465

39. Barr KM, Gershan JA, Johnson BD. Hematopoietic stem cell transplantation and lymphodepletion for the treatment of cancer Cancer Immunology: Bench to Bedside Immunotherapy of Cancers. 1 January 2015:189-201.

40. Xia G, Zhang Z, Johnson BD. Prevention of heart allograft rejection by immunotherapy with ex vivo-expanded Foxp3⁺CD4⁺CD25⁺ natural regulatory T cells Heart Transplantation: Indications and Contraindications, Procedures and Complications. January 2011:25-49.

41. Hallett W, Johnson B. Exploiting arginase to prevent GVHD Blood. 16 December 2010;116(25):5440-5441.

42. Orentas RJ, Johnson B, Hodge J. Cancer Vaccines: Progress and Promise Cancer Vaccines and Tumor Immunity. 1 March 2007:1-11.

43. Jing W, Johnson BD. Tumor Vaccination after Autologous HSCT: What has been Learned from Experimental Models Cancer Vaccines and Tumor Immunity. 1 March 2007:205-215.

44. Xia G, Zhang Z, Johnson BD. Prevention of heart allograft rejection by immunotherapy with ex vivo-expanded Foxp3⁺CD4⁺CD25⁺ natural regulatory T cells Heart Transplantation: Indications and Contradictions, Procedures and Complications. 1 January 2009:25-49.

45. Shah NN, Johnson BD, Fenske TS, Raj RV, Hari P. Intrathecal chemotherapy for management of steroid-refractory CAR T-cell-associated neurotoxicity syndrome. Blood Adv. 2020 May 26;4(10):2119-2122. PMCID: PMC7252557

46. Badar T, Johnson BD, Hamadani M. Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma. Bone Marrow Transplant. 2021 Mar;56(3):683-685.

47. Chhabra S, Thapa B, Szabo A, Konings S, D'Souza A, Dhakal B, Jerkins JH, Pasquini MC, Johnson BD, Hari PN, Hamadani M. Utilization and Cost Implications of Hematopoietic Progenitor Cells Stored for a Future Salvage Autologous Transplantation or Stem Cell Boost in Myeloma Patients. Biol Blood Marrow Transplant. 2020 Nov;26(11):2011-2017.

48. Shah NN, Jerkins JH, Johnson BD, Hari P. Treatment-Emergent Tumor Lysis Syndrome With PI3Kδ-γ Inhibition After CAR T-Cell Therapy for Chronic Lymphocytic Leukemia. JCO Oncol Pract. 2020 Sep;16(9):613-614.

49. Shah NN, Johnson BD, Schneider D, Zhu F, Szabo A, Keever-Taylor CA, Krueger W, Worden AA, Kadan MJ, Yim S, Cunningham A, Hamadani M, Fenske TS, Dropulić B, Orentas R, Hari P. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat Med. 2020 Oct;26(10):1569-1575.

50. Lenarczyk M, Laiakis EC, Mattson DL, Johnson BD, Kronenberg A, North PE, Komorowski R, Mäder M, Baker JE. Irradiation of the kidneys causes pathologic remodeling in the nontargeted heart: A role for the immune system. FASEB Bioadv. 2020 Dec;2(12):705-719. PMCID: PMC7734425

51. Vonderhaar EP, Barnekow NS, McAllister D, McOlash L, Eid MA, Riese MJ, Tarakanova VL, Johnson BD, Dwinell MB. STING Activated Tumor-Intrinsic Type I Interferon Signaling Promotes CXCR3 Dependent Antitumor Immunity in Pancreatic Cancer. Cell Mol Gastroenterol Hepatol. 2021;12(1):41-58. PMCID: PMC8081932

52. Zurko J, Chaney K, Astle JM, Johnson BD, Hari P, Shah NN. PD-1 blockade after bispecific LV20.19 CAR T modulates CAR T-cell immunophenotype without meaningful clinical response. Haematologica. 2021 Oct 01;106(10):2788-2790. PMCID: PMC8485669

53. Miller MS, Allen PJ, Brown PH, Chan AT, Clapper ML, Dashwood RH, Demehri S, Disis ML, DuBois RN, Glynn RJ, Kensler TW, Khan SA, Johnson BD, Liby KT, Lipkin SM, Mallery SR, Meuillet EJ, Roden RBS, Schoen RE, Sharp ZD, Shirwan H, Siegfried JM, Rao CV, You M, Vilar E, Szabo E, Mohammed A. Meeting Report: Translational Advances in Cancer Prevention Agent Development Meeting. J Cancer Prev. 2021 Mar 30;26(1):71-82. PMCID: PMC8020174

54. AbuEid M, McAllister DM, McOlash L, Harwig MC, Cheng G, Drouillard D, Boyle KA, Hardy M, Zielonka J, Johnson BD, Hill RB, Kalyanaraman B, Dwinell MB. Synchronous effects of targeted mitochondrial complex I inhibitors on tumor and immune cells abrogate melanoma progression iScience. 25 June 2021;24(6).

55. Palen K, Zurko J, Johnson BD, Hari P, Shah NN. Manufacturing chimeric antigen receptor T cells from cryopreserved peripheral blood cells: time for a collect-and-freeze model? Cytotherapy. 2021 Nov;23(11):985-990.

56. Pan J, Chen Y, Zhang Q, Khatun A, Palen K, Xin G, Wang L, Yang C, Johnson BD, Myers CR, Sei S, Shoemaker RH, Lubet RA, Wang Y, Cui W, You M. Inhibition of lung tumorigenesis by a small molecule CA170 targeting the immune checkpoint protein VISTA. Commun Biol. 2021 Jul 23;4(1):906. PMCID: PMC8302676

57. AbuEid M, McAllister DM, McOlash L, Harwig MC, Cheng G, Drouillard D, Boyle KA, Hardy M, Zielonka J, Johnson BD, Hill RB, Kalyanaraman B, Dwinell MB. Synchronous effects of targeted mitochondrial complex I inhibitors on tumor and immune cells abrogate melanoma progression. iScience. 2021 Jun 25;24(6):102653. PMCID: PMC8220235

58. Zurko JC, Johnson BD, Aschenbrenner E, Fenske TS, Hamadani M, Hari P, Shah NN. Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity Syndrome. JAMA Oncol. 2022 May 01;8(5):773-775. PMCID: PMC8914887

59. Huang M, Xiong D, Pan J, Zhang Q, Wang Y, Myers CR, Johnson BD, Hardy M, Kalyanaraman B, You M. Prevention of Tumor Growth and Dissemination by In Situ Vaccination with Mitochondria-Targeted Atovaquone. Adv Sci (Weinh). 2022 Apr;9(12):e2101267. PMCID: PMC9036031

60. Mohammed A, Dashwood RH, Dickinson S, Disis ML, Jaffee EM, Johnson BD, Khleif SN, Pollak MN, Schlom J, Shoemaker RH, Stanton SE, Wondrak GT, You M, Zhu H, Miller MS. Translational Advances in Cancer Prevention Agent Development (TACPAD) Virtual Workshop on Immunomodulatory Agents: Report. J Cancer Prev. 2021 Dec 30;26(4):309-317. PMCID: PMC8749317

61. Taylor MR, Hillard CJ, Drobyski WR, Szabo A, Johnson BD, Zhu F, Raison CL, Cole SW, Knight JM. The effect of tocilizumab on patient reported outcomes and inflammatory biomarkers in hematopoietic cell transplantation. Brain Behav Immun Health. 2022 Aug;23:100480. PMCID: PMC9213229

62. Zurko JC, Xu H, Chaney K, Schneider D, Szabo A, Hari P, Johnson BD, Shah NN. Bispecific targeting of CD20 and CD19 increases polyfunctionality of chimeric antigen receptor T-cell products in B-cell malignancies. Cytotherapy. 2022 Aug;24(8):767-773.

63. Chu Y, Talano JA, Baxter-Lowe LA, Verbsky JW, Morris E, Mahanti H, Ayello J, Keever-Taylor C, Johnson B, Weinberg RS, Shi Q, Moore TB, Fabricatore S, Grossman B, van de Ven C, Shenoy S, Cairo MS. Donor chimerism and immune reconstitution following haploidentical transplantation in sickle cell disease. Front Immunol. 2022;13:1055497. PMCID: PMC9780682

64. Zurko JC, Fenske TS, Johnson BD, Bucklan D, Szabo A, Xu H, Chaney K, Hamadani M, Hari P, Shah NN. Long-term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific LV20.19 CAR T-cells. Am J Hematol. 2022 Dec;97(12):1580-1588.

65. Pan J, Xiong D, Zhang Q, Palen K, Shoemaker RH, Johnson B, Sei S, Wang Y, You M. Precision immunointerception of EGFR-driven tumorigenesis for lung cancer prevention. Front Immunol. 2023;14:1036563. PMCID: PMC9982083

66. Knight JM, Hackett E, Szabo A, Wu R, Sauber G, Johnson B, Cusatis RN, Aughey E, Cole SW, Hillard CJ, Shah NN. Associations between socioeconomic status and bispecific LV20.19 CAR T-cell therapy outcomes. Haematologica. 2023 Feb 01;108(2):588-593. PMCID: PMC9890001

67. Barr KM, Khoshbin AP, Gershan JA, Johnson BD. Hematopoietic stem cell transplantation and lymphodepletion for the treatment of cancer Cancer Immunology: Bench to Bedside Immunotherapy of Cancers, Second Edition. 24 September 2020:143-156.

68. Chu Y, Milner J, Lamb M, Maryamchik E, Rigot O, Ayello J, Harrison L, Shaw R, Behbehani GK, Mardis ER, Miller K, Prakruthi Rao Venkata L, Chang H, Lee D, Rosenthal E, Kadauke S, Bunin N, Talano JA, Johnson B, Wang Y, Cairo MS. Manufacture and Characterization of Good Manufacturing Practice-Compliant SARS-COV-2 Cytotoxic T Lymphocytes. J Infect Dis. 2023 Mar 28;227(6):788-799.

69. Leahy AB, Li Y, Talano JA, Elgarten CW, Seif AE, Wang Y, Johnson B, Monos DS, Kadauke S, Olson TS, Freedman J, Wray L, Grupp SA, Bunin N. Unrelated donor α/β T cell- and B cell-depleted HSCT for the treatment of pediatric acute leukemia. Blood Adv. 2022 Feb 22;6(4):1175-1185. PMCID: PMC8864664

70. Chung DJ, Shah N, Wu J, Logan B, Bisharat L, Callander N, Cheloni G, Anderson K, Chodon T, Dhakal B, Devine S, Somaiya Dutt P, Efebera Y, Geller N, Ghiasuddin H, Hematti P, Holmberg L, Howard A, Johnson B, Karagkouni D, Lazarus HM, Malek E, McCarthy P, McKenna D, Mendizabal A, Nooka A, Munshi N, O'Donnell L, Rapoport AP, Reese J, Rosenblatt J, Soiffer R, Stroopinsky D, Uhl L, Vlachos IS, Waller EK, Young JW, Pasquini MC, Avigan D. Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401. Clin Cancer Res. 2023 Dec 01;29(23):4784-4796. PMCID: PMC10690096

1. Johnson BD. Alloantigen-specific regulatory T cells, Blood, 103:400, 2004.

2. Hallett W, Johnson B. Exploiting arginase to prevent GVHD, Blood, 116:5440, 2010.

3. Johnson BD. Exciting new murine model of cGVHD. Blood. 2012 Feb 09;119(6):1331-2.

4. Kindt N, Preillon J, Kaltner H, Gabius HJ, Chevalier D, Rodriguez A, Johnson BD, Megalizzi V, Decaestecker C, Laurent G, Saussez S. Macrophage migration inhibitory factor in head and neck squamous cell carcinoma: clinical and experimental studies. J Cancer Res Clin Oncol. 2013 May;139(5):727-37.

5. Barr KM, Jing W, Hallett WH, Gershan JA, Johnson BD. Examining T cells at vaccine sites of tumor-bearing hosts provides insights to dysfunctional T-cell immunity. J Immunother. 2013 Jan;36(1):41-51. PMCID: PMC3521867

1. Jing W, Yan X, Orentas RJ, Johnson BD. Syngeneic Neuroblastoma Cells Transiently-Transfected with Plasmid DNA Vectors Encoding a Panel of Immune Stimulatory Molecules Can Induce Anti-Tumor Immunity Early after BMT. Biol Blood Marrow Tr. Feb 2006;13(suppl 1)(2):93.

2. Zhou Q, Orentas RJ, Johnson BD. Determining the Cellular Immune Response to a Subcutaneous Cell-Based Vaccine for Neuroblastoma. J Immunol. 2006 Apr 1;176 Suppl:S1-322.

3. Orentas R, Yan X, Johnson B.Tumor-Derived Macrophage Migration Inhibitory Factor (MIF) Inhibits Lymphocyte Activation. J Immunol. 2006 Apr 1;176 Suppl:S1-322.

4. Johnson BD, Jing W, Orentas RJ. CD25+ Regulatory T Cell Inhibition Enhances Vaccine-Induced Immunity to Neuroblastoma. J Immunother. 2006 Nov/Dec;29(6):665-666.

5. Jing W, Orentas RJ, Johnson BD. Vaccine-Induced Anti-Neuroblastoma Immunity Early after HSCT Arises in the Presence of Foxp3+CD25+CD4+ T Cells. Blood (ASH Annual Meeting Abstracts); Nov 2006;108:3692.

6. Orentas R, Zheng J, Kohler M.E, Khan J, Johnson B: Discovery of New Immunologic Targets in Neuroblastoma by Vaccination in the Context of Regulatory T Cell Depletion: lmmunodominance of the DEK Oncogene. Presented at the Advances in Neuroblastoma Research 2006 Meeting, Los Angeles, CA, May 17-20, 2006

7. Orentas RJ, Jing W, Yan X, Johnson BD. Effective Immunotherapy for Neuroblastoma Requires HSCT and T Cell Transfer. Biol Blood Marrow Tr. Feb 2007,13(suppl)(2):29.

8. Jing W, Yan X, Orentas RJ, Johnson BD. A Combination of Hematopoietic Stem Cell Transplantation (HSCT), Adoptive Immunotherapy, and Tumor Vaccination can Eliminate Established Tumor. J Immunother. Nov/Dec 2007;30(8):870.

9. Zhou Q, Yan X, Orentas RJ, Johnson BD. Tumor-Derived Macrophage Migration Inhibitory Factor (MIF) Inhibits Immune Reactivity to Neuroblastoma In Vivo. J Immunother. Nov/Dec 2007;30(8):890.

10. Yan X, Johnson BD, Orentas RJ. A Cell-Based Vaccine for Neuroblastoma Induces VLA-2 (CD49b) on CD8+ T Effector/Memory cells Via CD137L. J Immunother. 2007 Nov/Dec;30(8):867.

11. Doffek K, Yan X, Sugg SL, Johnson B, Shilyansky J: Targeting Phosphatidylserine Promotes Immunity to Neu roblastoma. Presented at the American Association for Cancer Research annual meeting, Los Angeles, CA, April 14-18, 2007.

12. Hallett WHD, Drobyski WR, Johnson BD. B7-H1 Blockade Enhances Immunotherapy for Multiple Myeloma. AIC2009 Program Booklet, p39, http://autumnimmunology.org/flipbook/AIC2009ProgramBook/index.html.

13. Barr K, Johnson BD. Neuroblastoma Suppresses Anti-Tumor Immune Responses at Vaccine Sites. AIC2010 Program Booklet, p71, http://autumnimmunology.org/flipbook/AIC2010ProgramBook/index.html.

14. Jing W, Yan X, Orentas RJ, Johnson BD: A Combination of Hematopoietic Stem Cell Transplantation (HSCT), Adoptive Immunotherapy and Tumor Vaccination can Eliminate Established Tumor. Presented at the Annual Meeting for the International Society for Biological Therapy of Cancer, Boston, MA, November 1-4, 2007.

15. Gershan J, Yan X, Johnson BD: Immune Suppression is Transferred by Exposure to Supernatant from MIF Overexpressing Tumor. Presented at the AACR special conference entitled Tumor Immunology: New Perspectives, Miami, FL, December 2-5, 2008.

16. Kohler ME, Chen Q, Hallett W H, Johnson BD: Induction of "Stemness" Genes in CDS T Cells after Vaccination of Tum or-Free Mice with a Cell-Based Vaccine . Presented at the AACR special conference entitled "Tumor Immunology: New Perspectives", Miami , FL, December 2-5, 2008

17. Jing W, Johnson BD. Mechanisms of CD8 Memory Loss to Neuroblastoma after Autologous Hematopoietic Stem Cell Transplantation. J Immunother. Nov-Dec 2009;32(9):944.

18. Kearl T, Johnson BD. Indoleamine 2,3-Dioxygenase Expression by Murine T Cells Following In Vitro Exposure to Tumor Culture Supernatant. J Immunother. Nov-Dec 2009;32(9):988.

19. Jing W, Johnson BD. Depletion of CD4 T Cells Leads to Increased Tumor Immunity after HSCT Immunotherapy but Results in Loss of Memory. Biol Blood Marrow Tr. Feb 2009;15(2 suppl):83-84.

20. Hallett WHD, Drobyski WR, Johnson BD. Blockade of the PD-1 Pathway Improves Immunotherapy for Myeloma. J Immunother. Dec 2010;33(8):870.

21. Hallett WHD, Drobyski WR, Johnson BD. Inhibiting Immune Suppressive Pathways to Improve Immunotherapy for Myeloma. Biology of Blood and Marrow Transplantation. Feb 2011;17(2 suppl):S178-S179.

22. Barr K, Johnson BD: Examining T Cells at the Vaccine Sites of Tumor-Bearing Hosts Provide Insights to Dysfunctional Tumor Immunity Presented at a National Cancer Institute sponsored meeting entitled "Cancer Immunology and Immunotherapy: Building on Success", Bethesda, MD, September 22-23, 2011

23. Kearl T, Johnson BD: Programmed Death Receptor as a Marker of Tumor- Reactive Cells in a Murine Model of Multiple Myeloma. Presented at a National Cancer Institute sponsored meeting entitled "Cancer Immunology and Immunotherapy: Building on Success", Bethesda, MD, September 22-23, 20 II.

24. Kearl TJ, Jing W, Johnson BD: PD-1/PD-Ll Blockade after Transient Lymphodepletion to Treat Myeloma. Oral presentation at the Annual Meeting for the Society for Immunotherapy of Cancer (SITC), Bethesda, MD, October 26-28,2012

25. Gershan J, Barr K, Weber J, Johnson BD: Cyclophosphamide in Combination with Tumor Lysate and TLR 9 Ligand Regresses Murine, Neuroblastoma. Presented at the Annual Meeting for the Society for Immunotherapy of Cancer (SITC), National Harbor, MD, November 7-10, 2013.

26. Jing W, Weber J, Tlomak D, McOiash L, Gershan J, Sabatos-Peyton C, Johnson BD: Combined Immune Checkpoint Protein Blockade and Lymphodepletion as Immunotherapy for Myeloma. Submitted for presentat ion at the Federation of Clinical Immunology Societies annual meeting in Chicago, IL, June, 2104

27. Jing W, Gershan JA, Weber J, Tlomak D, McOlash L, Sabatos-Peyton C, Johnson BD. Combined Immune Checkpoint Protein Blockade and Lymphodepletion as Immunotherapy for Myeloma. 43rd Annual Autumn Immunology Conference, Chicago, IL. Nov 2014

28. Tsai S., Aldakkak M., McOlash L., Grewal J., Johnson B., Evans D., Mackinnon A.C., Gershan J.: Peripheral Immune Biomarkers as a Predictor of Pancreatic Cancer Progression. Presented at the AACR special conference titled “Pancreatic Cancer: Advances in Science and Clinical Care, Orlando, FL, May 12-15, 2016.

29. Jing W., Gershan J., Blitzer G., Weber J., McOlash L., and Johnson B.D.: Adoptive Transfer of Ex Vivo-Expanded PD-1+CD8+ and CD4+ T Cells Eliminates Myeloma in Mice. Presented at the Annual Meeting for the Society for Immunotherapy of Cancer (SITC), National Harbor, MD, November 11-13, 2016